Pichlík T, Rob L, Robová H, Halaška M J, Drozenová J, Hruda M, Drochýtek V
Ceska Gynekol. 2019 Spring;84(3):172-176.
To evaluate the risk of involvement of sentinel lymph nodes in cervical cancer stage IA1 with lymphovascular space invasion and IA2 using the detection of sentinel lymph nodes.
Original article.
Department of Gynecology and Obstetrics 3rd Faculty of Medicine, Charles University, Faculty Hospital Královské Vinohrady, Prague; Oncogynecological centrum; Department of Pathology 3rd Faculty of Medicine, Charles University, Faculty Hospital Kralovské Vinohrady, Prague.
The study included women from prospective protocols LAP I and LAP II with cervical cancer stage IA1 with lymphovascular space invasion and stage IA2 from 2002 to 2018 classified according to FIGO 2014 staging, TNM 8. Detection of sentinel lymph nodes throughout this period was performed using ultra-short protocol with Tc and patent blau and also by histopathological examination.
In the first group (28 women) with stage IA1 and lymphovascular space invasion diagnosed from cone biopsy there were two women with positive lymph nodes (7.1%). In the group stage IA2 (34 women) there were 13 women (38.2%) with positive lymphovascular space invasion and two women had positive lymph nodes (5.9%). The risk of positive lymph nodes for stage IA1 with lymphovascular space invasion and for stage IA2 is not statistically significant OR = 0.8125 (95% CI 0.1070-6.172).
The detection of sentinel lymph nodes aids to individualize the therapy of early stage cervical cancer and helps to reduce the radicalization of surgery. The risk of positive lymph nodes in stage IA1 with lymphovascular space invasion and stage IA2 with/without lymphovascular space invasion is the same. The results confirm, that the detection of sentinel lymph nodes in stage IA1 with lymphovascular space invasion is fully indicated.
通过前哨淋巴结检测评估伴有脉管间隙浸润的IA1期和IA2期宫颈癌前哨淋巴结受累风险。
原创文章。
布拉格查理大学医学院第三附属医院妇产科;肿瘤妇科中心;布拉格查理大学医学院第三附属医院病理科。
本研究纳入2002年至2018年符合2014年FIGO分期、TNM 8标准的前瞻性LAP I和LAP II方案中的伴有脉管间隙浸润的IA1期宫颈癌及IA2期宫颈癌女性患者。在此期间,使用锝和专利蓝超短方案并通过组织病理学检查进行前哨淋巴结检测。
第一组(28例女性)为经锥形活检诊断的伴有脉管间隙浸润的IA1期,其中2例女性淋巴结阳性(7.1%)。IA2期组(34例女性)中,13例女性有脉管间隙浸润阳性(38.2%),2例女性淋巴结阳性(5.9%)。伴有脉管间隙浸润的IA1期和IA2期淋巴结阳性风险无统计学意义,OR = 0.8125(95% CI 0.1070 - 6.172)。
前哨淋巴结检测有助于早期宫颈癌治疗个体化并有助于减少手术的根治性。伴有脉管间隙浸润的IA1期和伴有/不伴有脉管间隙浸润的IA2期淋巴结阳性风险相同。结果证实,伴有脉管间隙浸润的IA1期进行前哨淋巴结检测是完全必要的。